Dual Antiplatelet and Anticoagulation Regimens for Women Undergoing Percutaneous Coronary Intervention

Aman Kansal; Pooja Swamy; Jennifer A Rymer

doi:10.1016/j.iccl.2024.08.012

Dual Antiplatelet and Anticoagulation Regimens for Women Undergoing Percutaneous Coronary Intervention

Interv Cardiol Clin. 2025 Jan;14(1):29-36. doi: 10.1016/j.iccl.2024.08.012. Epub 2024 Oct 10.

Authors

Aman Kansal¹, Pooja Swamy², Jennifer A Rymer³

Affiliations

¹ Duke University, Durham, NC, USA.
² Loma Linda Health, Loma Linda, CA, USA.
³ Duke University, Durham, NC, USA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. Electronic address: [email protected].

PMID: 39537286
DOI: 10.1016/j.iccl.2024.08.012

Abstract

Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is necessary for preventing stent thrombosis and ensuring long-term cardiovascular protection. It is important to be thoughtful in balancing thrombotic and bleeding risk when deciding therapy regimen and duration. Revascularization randomized trials have studied many specific, at-risk populations; however, women remain underrepresented. Although there is evidence to support shortened DAPT duration in women, especially those at higher bleeding risk or on chronic oral anticoagulation, we need trials specifically enrolling and focusing on women.

Keywords: Bleeding risk; Dual antiplatelet therapy; Duration; PCI; Women.

Publication types

Review

MeSH terms

Anticoagulants* / administration & dosage
Anticoagulants* / adverse effects
Anticoagulants* / therapeutic use
Coronary Artery Disease / surgery
Dual Anti-Platelet Therapy / methods
Female
Hemorrhage / chemically induced
Hemorrhage / prevention & control
Humans
Percutaneous Coronary Intervention* / methods
Platelet Aggregation Inhibitors* / administration & dosage
Platelet Aggregation Inhibitors* / therapeutic use

Substances

Anticoagulants
Platelet Aggregation Inhibitors